Ulf Björklund

Ulf Björklund is the current Chairman at LipUm AB, and has previously held notable positions at various companies, including CEO of OxyPharma and Aprea AB. Ulf has also been Board Member at Annexin Pharmaceuticals AB and Chairman Of The Board Of Directors at Wnt Research AB.

Björklund's career in the pharmaceutical industry began in 1998 as Head Clinical Operations for the Nordic countries at Pharmacia AB. In 2002, they became CEO of OxyPharma, where they remained until 2010. During their time as CEO, the company was engaged in the development of drugs for the treatment of rheumatoid arthritis (RA) and multiple sclerosis (MS).

In 2010, Björklund became CEO of Aprea AB, where they remained until 2016. During their time as CEO, the company developed drugs for the treatment of cancer patients with a p53 mutation. In 2016, they managed to bring in 60 MUSD from new investors to ensure further development of the Company.

Björklund has been Chairman at LipUm AB since 2019.

Ulf Björklund studied pharmacy at Uppsala University and obtained a master's degree.